GlassScriptPhysician profile
Aviva Tobin-Hess
NPI 1598297376
$939.12
in general payments reported to CMS, 2019-2025
22 companies · $183 in 2025
The $183 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $32.14 · 2022: $156 · 2023: $421 · 2024: $147 · 2025: $183.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $751.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $751.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $234.17 | 2021-2025 | Vraylar, Ubrelvy |
| E.R. Squibb & Sons, L.L.C. | $128.11 | 2023 | Camzyos |
| Heartflow, INC. | $68.82 | 2024 | |
| Lilly USA, LLC | $59.57 | 2022-2024 | Zepbound, Mounjaro, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $54.66 | 2025 | Jardiance |
| Astellas Pharma US INC | $52.78 | 2023-2024 | Veozah |
| Sanofi Pasteur INC. | $45.65 | 2023-2024 | |
| Novo Nordisk INC | $38.81 | 2023-2025 | Ozempic, Rybelsus |
| Almatica Pharma LLC | $29.40 | 2023 | Loreev Xr, Gralise |
| Takeda Pharmaceuticals U.S.A., INC. | $21.65 | 2023 | Vpriv |
| Dexcom, INC. | $21.00 | 2022 | |
| Exact Sciences Corporation | $20.24 | 2024 | Cologuard Collection Kit |
| Amgen INC. | $19.56 | 2023 | Otezla, Repatha |
| Merck Sharp & Dohme LLC | $18.82 | 2023 | Pneumovax 23, Vaxneuvance, Gardasil 9 |
| Amneal Pharmaceuticals LLC | $17.44 | 2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $17.42 | 2023 | |
| Genentech USA, INC. | $17.03 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $15.97 | 2024 | |
| Idorsia Pharmaceuticals US INC | $15.50 | 2023 | Quviviq |
| Glaxosmithkline, LLC. | $15.18 | 2023 | Shingrix, Arexvy |
| Sumitomo Pharma America, INC. | $13.86 | 2025 | Myfembree |
| Bavarian Nordic A/S | $13.48 | 2025 | Vivotif |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aviva Tobin-Hess listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.